What is Albizia anthelmintica traditionally used for?

Albizia anthelmintica has been used primarily as an anthelmintic — a remedy to expel intestinal parasites — in Somali and Ethiopian traditional medicine, with bark and root decoctions administered orally to humans and livestock. In Namibia, it has also been employed against microbial infections. These uses reflect the broader ethnobotanical role of Albizia species in African traditional healing systems, though none have been validated through clinical trials.

What bioactive compounds are found in Albizia anthelmintica?

The leaves of Albizia anthelmintica contain eight characterized phenolic compounds: gallic acid, quercetin, kaempferol, quercetin-3-O-β-D-glucopyranoside, kaempferol-3-O-β-D-glucopyranoside, quercetin-3-O-β-galactopyranoside, and two galloylated flavonoid glycosides. Total phenolic content in leaf extract was measured at 1741.08 mg GAE/100 g, and total flavonoids at 366.80 mg QE/100 g. Alkaloids and tannins are also present in ethanolic extracts of roots and stem bark.

Is there clinical trial evidence supporting Albizia anthelmintica for humans?

No human clinical trials have been conducted on Albizia anthelmintica as of available published literature. All efficacy data come from preclinical animal studies — including rodent anti-inflammatory and analgesic models — and in vitro antioxidant and antibacterial assays. The ingredient currently has preliminary-level evidence, and its use in humans should be considered investigational.

How does Albizia anthelmintica reduce inflammation in animal studies?

In rat carrageenan-induced paw edema models, aqueous ethanol leaf extracts at 200–400 mg/kg reduced edema by 37.87–44.35% at 3–4 hours, compared to 52.56–54.80% for reference NSAIDs etodolac and indomethacin at 5 mg/kg. The anti-inflammatory effect is attributed to the flavonoid constituents quercetin and kaempferol, which in broader pharmacological literature inhibit prostaglandin-synthesizing enzymes COX-1 and COX-2, though direct enzyme assays on this species have not been published.

Is Albizia anthelmintica safe to use as a supplement?

There are no published human safety studies, toxicology evaluations, or adverse event data for Albizia anthelmintica, making it impossible to confirm its safety as a supplement by current standards. Rodent studies at 200–400 mg/kg reported no overt acute toxicity, but this does not define a safe human dose. Use during pregnancy, lactation, or alongside prescription medications — particularly anticoagulants or cytochrome P450-metabolized drugs — is unsupported and potentially risky given the known pharmacological activities of its flavonoid constituents.

What is the most effective form of Albizia anthelmintica for anti-inflammatory benefits?

Aqueous ethanol leaf extracts have demonstrated the strongest anti-inflammatory activity in research, reducing paw edema by 37.87–44.35% in animal models at doses of 200–400 mg/kg. The extraction method appears critical, as ethanol-based preparations better isolate the active phenolic compounds (quercetin and kaempferol glycosides) responsible for modulating inflammatory mediators compared to other extraction methods.

Who should avoid Albizia anthelmintica supplementation?

Pregnant and nursing women should avoid Albizia anthelmintica due to its traditional use as an anthelmintic agent and lack of safety data in these populations. Individuals with phenolic compound sensitivities or those taking anticoagulant medications should consult a healthcare provider before use, as the quercetin and kaempferol glycosides may have mild blood-thinning properties.

How does Albizia anthelmintica compare to other herbal anti-inflammatories in terms of potency?

Albizia anthelmintica's 37–44% reduction in paw edema places it among moderate-strength herbal anti-inflammatories, though direct comparative studies with other herbs are limited. Its dual action—combining anti-inflammatory and analgesic effects (52–76% pain protection in animal models)—provides broader symptom relief than single-action herbs, making it potentially valuable for inflammatory pain conditions.

Albizia anthelmintica

Albizia anthelmintica leaves contain flavonoid glycosides including quercetin-3-O-β-D-glucopyranoside and kaempferol derivatives alongside gallic acid, which exert free radical scavenging and anti-inflammatory activity through phenolic antioxidant pathways. In rat models, aqueous ethanol leaf extracts at 200–400 mg/kg reduced carrageenan-induced paw edema by 37.87–44.35%, while analgesic protection in mice reached 52.44–76.83% compared to aspirin controls, though no human clinical trials have been conducted.

Category: African Evidence: 1/10 Tier: Preliminary

Albizia anthelmintica — Hermetica Encyclopedia

Origin & History

Albizia anthelmintica is a deciduous tree native to sub-Saharan Africa, distributed across East Africa including Somalia, Ethiopia, Kenya, and extending southward to Namibia, typically growing in arid and semi-arid savanna woodland environments. It thrives in well-drained soils at low to mid elevations, often found in thornbush and dry woodland habitats. The species has not been formally cultivated for commercial herbal markets and is harvested from wild populations for traditional medicinal use.

Historical & Cultural Context

Albizia anthelmintica has a documented history of use as an anthelmintic agent among pastoral and agricultural communities in Somalia and Ethiopia, where the common name and species epithet both reflect its primary traditional role in expelling intestinal worms in humans and livestock. In Namibia, the plant has been employed in traditional preparations targeting microbial infections, with bark and root material typically forming the basis of decoctions and oral preparations. Albizia species as a genus have intersected with multiple traditional medicine systems, including traditional Chinese medicine, where related species have been used for sedative and anxiolytic purposes, though Albizia anthelmintica itself is geographically and ethnobotanically rooted in African healing traditions. The species represents a broader pattern of African savanna trees used in veterinary and human ethnomedicine where pharmaceutical access is limited, and its bioactive compound profile has only recently begun to receive formal scientific attention.

Health Benefits

- **Anti-inflammatory Activity**: Aqueous ethanol leaf extracts reduced carrageenan-induced paw edema in rats by 37.87–44.35% at 200–400 mg/kg doses, attributed to the phenolic constituents quercetin and kaempferol glycosides modulating inflammatory mediator activity.
- **Analgesic Effects**: In acetic acid-induced writhing mouse models, leaf extracts demonstrated 52.44–76.83% protection against pain responses, outperforming aspirin (5 mg/kg) at higher tested doses, suggesting peripherally mediated analgesic mechanisms.
- **Antioxidant Capacity**: The leaf extract exhibited potent DPPH free radical scavenging with an IC50 of 29.49 μg/ml, while isolated quercetin-3-O-β-D-glucopyranoside showed even greater activity at IC50 = 12.41 μg/ml, supported by a high total phenolic content of 1741.08 ± 0.05 mg GAE/100 g.
- **Antibacterial Properties**: Ethanolic extracts demonstrated dose-dependent inhibition of Staphylococcus aureus (ATCC 25923) growth, with measurable minimum inhibitory concentration values, consistent with traditional use against microbial infections in humans and livestock.
- **Traditional Anthelmintic Use**: The species name and primary ethnobotanical role reflect longstanding use as an anthelmintic agent in Somali and Ethiopian traditional medicine, with bark and root preparations employed against intestinal parasites, though modern mechanistic validation remains absent.
- **Phenolic Compound Richness**: The leaf matrix contains a flavonoid content of 366.80 ± 0.02 mg QE/100 g alongside eight characterized phenolic compounds including gallic acid and multiple quercetin and kaempferol glycosides, supporting broad biological activity across oxidative and inflammatory targets.

How It Works

The primary mechanistic basis for the observed biological activities lies in the phenolic compound profile of the leaves, particularly quercetin, kaempferol, gallic acid, and their glycosylated derivatives, which donate hydrogen atoms or electrons to neutralize free radicals as demonstrated by DPPH reduction assays at 517 nm. Quercetin and kaempferol are well-established inhibitors of pro-inflammatory enzymes including cyclooxygenase (COX) and lipoxygenase (LOX) in the broader literature, and their presence in this species provides a plausible molecular basis for the observed edema suppression in carrageenan models, though direct enzyme inhibition studies on Albizia anthelmintica extracts have not been published. Galloyl-substituted flavonoid glycosides such as quercetin-3-O-(6''-O-galloyl-β-D-glucopyranoside) and kaempferol-3-O-(6''-O-galloyl-β-D-glucopyranoside) may enhance binding affinity to biological targets due to the additional galloyl moiety increasing hydrophobic and hydrogen-bonding interactions. Antibacterial activity is consistent with phenolic membrane disruption mechanisms, though no receptor-level or gene expression data have been reported for this species specifically.

Scientific Research

The evidence base for Albizia anthelmintica is limited to a small number of preclinical in vitro and animal studies, with no published human clinical trials, randomized controlled trials, or systematic reviews identified in available literature. Phytochemical characterization studies identified eight flavonoid and phenolic compounds from leaf extracts for the first time, while separate in vivo studies using rat carrageenan paw edema and mouse writhing models provided quantified anti-inflammatory and analgesic outcomes at doses of 200–400 mg/kg. Antibacterial activity was assessed through in vitro disc diffusion and MIC assays against bacterial strains including Staphylococcus aureus ATCC 25923, yielding dose-dependent inhibition zones, though sample sizes and full methodological details were not consistently reported. The overall quality of evidence is low by clinical standards; results are preliminary and hypothesis-generating, and extrapolation to human therapeutic applications is not currently supported.

Clinical Summary

No human clinical trials have been conducted on Albizia anthelmintica, and all quantified efficacy data derive from preclinical animal and in vitro experiments. In the most informative animal study, aqueous ethanol leaf extracts at 200 and 400 mg/kg body weight reduced carrageenan-induced paw edema in rats by 37.87% and 44.35% respectively at 3–4 hours post-induction, compared to 52.56–54.80% reduction for reference drugs etodolac and indomethacin at 5 mg/kg. Analgesic testing in mice using the acetic acid writhing model showed 52.44–76.83% nociceptive protection across dose ranges, favorably compared to aspirin controls. Confidence in these results for human application remains very low due to the absence of pharmacokinetic data, dose-translation studies, and any phase of clinical investigation.

Nutritional Profile

Albizia anthelmintica is not consumed as a food source and has no characterized macronutrient or micronutrient profile in nutritional databases. Its phytochemical profile is the primary point of scientific interest: total phenolic content in leaf extract has been quantified at 1741.08 ± 0.05 mg gallic acid equivalents per 100 g of extract, and total flavonoid content at 366.80 ± 0.02 mg quercetin equivalents per 100 g. Identified phenolic compounds include gallic acid, quercetin, kaempferol, quercetin-3-O-β-D-glucopyranoside, kaempferol-3-O-β-D-glucopyranoside, quercetin-3-O-β-galactopyranoside, quercetin-3-O-(6''-O-galloyl-β-D-glucopyranoside), and kaempferol-3-O-(6''-O-galloyl-β-D-glucopyranoside). Alkaloids and tannins are also present in ethanolic extracts of leaves, roots, and stem bark, though these have not been isolated or quantified individually; bioavailability data for any constituent are entirely absent.

Preparation & Dosage

- **Aqueous Ethanol Extract (Research Form)**: Used at 200–400 mg/kg in animal studies; no human equivalent dose established due to absence of pharmacokinetic or allometric scaling data.
- **Ethanolic Extract (Phytochemical Studies)**: Prepared from dried leaves, roots, or stem bark via maceration or column chromatography; concentrations varied across studies with no standardization percentage defined.
- **Traditional Decoction**: Bark and root material boiled in water and administered orally as an anthelmintic in Somali and Ethiopian ethnomedicine; specific volumes and preparation durations are not formally documented.
- **Standardization**: No commercial supplement form, no standardized extract, and no defined marker compound percentage for quality control currently exists for this species.
- **Timing and Duration**: No clinical data to support specific dosing intervals, treatment duration, or timing recommendations; traditional use patterns have not been systematically recorded in accessible literature.

Synergy & Pairings

No published data describe synergistic combinations specifically involving Albizia anthelmintica extracts or its isolated constituents. Based on the phenolic compound profile, theoretical synergy may exist with other quercetin- or kaempferol-containing botanicals such as green tea (Camellia sinensis) or elderberry (Sambucus nigra), where additive antioxidant and anti-inflammatory effects are plausible through complementary free radical scavenging and COX pathway modulation. Gallic acid present in the extract has been reported to potentiate the antibacterial activity of conventional antibiotics against Staphylococcus species in separate literature, suggesting possible adjunctive value in anti-infective applications that warrants direct investigation.

Safety & Interactions

No formal toxicological studies, adverse event reporting, or human safety evaluations have been published for Albizia anthelmintica, representing a significant evidence gap that precludes definitive safety characterization. Preclinical studies at doses of 200–400 mg/kg in rodents reported no overt signs of acute toxicity, but this does not establish a maximum safe dose or define a therapeutic window for human use. No drug interaction data exist; however, given the presence of quercetin and kaempferol derivatives — compounds known in other contexts to inhibit cytochrome P450 enzymes and P-glycoprotein — theoretical interactions with anticoagulants, immunosuppressants, and drugs with narrow therapeutic indices cannot be excluded. Use during pregnancy, lactation, or in pediatric populations is unsupported by any safety data, and caution is warranted; the anthelmintic and tannin-containing preparations carry theoretical risks of gastrointestinal irritation at high doses based on constituent class properties.